Project Description

The Novel START (Novel Symbicort Turbuhaler Asthma Reliever Therapy) study is a 52- week, open label, parallel group, multicentre, phase III, randomised controlled trial to compare the efficacy and safety of three asthma treatment regimens.

Participants will be recruited from sites in 9 regions in 4 countries (New Zealand, Australia, Italy and the United Kingdom).